| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We tried to compare between "susceptible" and "resistant" cancers for the inhibition of PD-1/PD-L1 pathway, and attempted to describe a second immune checkpoint avoidance pathway by elucidating the differences. We found that we can uses B16F1 and B16F10 melanoma cells as a model of "susceptible" and "resistant" cancers for the inhibition of PD-1/PD-L1 pathway when transplanted via spleen. Mutagenesis and RNAseq analysis were performed after mutagenesis of PD-L1-deficient B16F1 cells, which were transformed to the PD-1/PD-L1 pathway "resistant cancer". By comparing the results from mouse with those of human immune checkpoint-sensitive and resistant patients, a total of 24 molecules were deduced as candidate master factors for the second avoidance mechanism from cancer immunity.
|
